Dopamine D3 Receptor in Parkinson Disease: A Prognosis Biomarker and an Intervention Target.
BDNF
Dopamine D3 receptor
Neuroinflammation
Parkinson disease
Progression
Survival
α-Synuclein
Journal
Current topics in behavioral neurosciences
ISSN: 1866-3370
Titre abrégé: Curr Top Behav Neurosci
Pays: Germany
ID NLM: 101535383
Informations de publication
Date de publication:
2023
2023
Historique:
pubmed:
18
6
2022
medline:
5
1
2023
entrez:
17
6
2022
Statut:
ppublish
Résumé
Parkinson disease (PD) dementia, pathologically featured as nigrostriatal dopamine (DA) neuronal loss with motor and non-motor manifestations, leads to substantial disability and economic burden. DA therapy targets the DA D3 receptor (D3R) with high affinity and selectivity. The pathological involvement of D3R is evidenced as an effective biomarker for disease progression and DA agnostic interventions, with compensations of increased DA, decreased aggregates of α-synuclein (α-Syn), enhanced secretion of brain-derived neurotrophic factors (BDNF), attenuation of neuroinflammation and oxidative damage, and promoting neurogenesis in the brain. D3R also interacts with D1R to reduce PD-associated motor symptoms and alleviate the side effects of levodopa (L-DOPA) treatment. We recently found that DA D2 receptor (D2R) density decreases in the late-stage PDs, while high D3R or DA D1 receptor (D1R) + D3R densities in the postmortem PD brains correlate with survival advantages. These new essential findings warrant renewed investigations into the understanding of D3R neuron populations and their cross-sectional and longitudinal regulations in PD progression.
Identifiants
pubmed: 35711029
doi: 10.1007/7854_2022_373
pmc: PMC10034716
mid: NIHMS1880635
doi:
Substances chimiques
Receptors, Dopamine D3
0
Dopamine
VTD58H1Z2X
Receptors, Dopamine D1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
89-107Subventions
Organisme : NINDS NIH HHS
ID : R01 NS092865
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS123571
Pays : United States
Organisme : NINDS NIH HHS
ID : R03 NS090214
Pays : United States
Informations de copyright
© 2022. The Author(s), under exclusive license to Springer Nature Switzerland AG.
Références
Brain Res. 1999 Mar 20;822(1-2):126-31
pubmed: 10082890
Am J Psychiatry. 1990 Jun;147(6):719-24
pubmed: 2343913
Synapse. 1998 Sep;30(1):88-96
pubmed: 9704885
J Neurosci Res. 2010 Aug 15;88(11):2513-23
pubmed: 20623619
Neurotox Res. 2013 Nov;24(4):523-31
pubmed: 23820985
Exp Neurol. 2012 Oct;237(2):355-62
pubmed: 22836146
Endocrinology. 1985 Aug;117(2):690-7
pubmed: 4017954
Eur J Pharmacol. 1988 Mar 1;147(2):249-58
pubmed: 3130270
Br J Pharmacol. 2006 Jan;147 Suppl 1:S136-44
pubmed: 16402097
Mov Disord. 1998 Sep;13(5):788-97
pubmed: 9756147
Expert Opin Drug Discov. 2016 Jul;11(7):641-64
pubmed: 27135354
Brain Res. 2002 Nov 15;955(1-2):138-52
pubmed: 12419530
Bioorg Med Chem. 2005 Jan 3;13(1):77-87
pubmed: 15582454
Ann Neurol. 2013 Mar;73(3):390-6
pubmed: 23423933
Synapse. 2011 Aug;65(8):724-32
pubmed: 21132811
Brain Res. 2007 Jul 30;1160:113-23
pubmed: 17573046
Front Pharmacol. 2014 Jul 10;5:161
pubmed: 25071579
Nature. 1990 Sep 13;347(6289):146-51
pubmed: 1975644
Cell Tissue Res. 2004 Oct;318(1):121-34
pubmed: 15338272
Ann Neurol. 2014 Sep;76(3):393-402
pubmed: 25043598
Eur Neuropsychopharmacol. 2008 Aug;18(8):551-6
pubmed: 18284941
Synapse. 2009 Jun;63(6):462-75
pubmed: 19217026
Eur J Pharmacol. 1992 Feb 11;211(2):189-94
pubmed: 1351846
Ann Clin Transl Neurol. 2019 Aug;6(8):1423-1434
pubmed: 31402620
J Pharmacol Exp Ther. 2006 Jan;316(1):189-99
pubmed: 16188953
PLoS One. 2012;7(11):e49483
pubmed: 23185343
J Neurosci. 2012 Jan 25;32(4):1353-9
pubmed: 22279219
Brain. 2013 Aug;136(Pt 8):2419-31
pubmed: 23884810
J Auton Pharmacol. 1990;10 Suppl 1:s53-60
pubmed: 1983009
Exp Neurol. 2003 Nov;184 Suppl 1:S68-79
pubmed: 14597329
J Neurosci. 1996 Oct 1;16(19):6100-6
pubmed: 8815892
Neuroscience. 2013 Sep 17;248:112-26
pubmed: 23732230
Biochem Soc Trans. 2018 Aug 20;46(4):891-909
pubmed: 30026371
J Cent Nerv Syst Dis. 2017 Aug 16;9:1179573517726335
pubmed: 28855798
Neuroreport. 2011 Jul 13;22(10):489-93
pubmed: 21642879
Neurology. 2011 Aug 23;77(8):767-74
pubmed: 21832216
Synapse. 2015 Dec;69(12):577-91
pubmed: 26422464
Parkinsons Dis. 2019 Jul 4;2019:7975407
pubmed: 31354934
Bioorg Med Chem Lett. 2015 Feb 1;25(3):519-23
pubmed: 25556097
Ann N Y Acad Sci. 2014 Nov;1329:45-66
pubmed: 25145951
Synapse. 2010 Jun;64(6):449-59
pubmed: 20175227
Ann Neurol. 1993 Sep;34(3):331-8
pubmed: 8363350
Neurosci Lett. 2013 Dec 17;557 Pt B:123-8
pubmed: 24157858
Arch Neurol. 2004 May;61(5):641-4
pubmed: 15148138
Acta Neuropathol. 1992;83(4):352-60
pubmed: 1374203
J Biol Chem. 1982 Jun 10;257(11):6351-61
pubmed: 6176582
Exp Neurol. 2011 Dec;232(2):333-8
pubmed: 21963652
Am J Nucl Med Mol Imaging. 2016 Nov 30;6(6):301-309
pubmed: 28078183
FASEB J. 1998 Jul;12(10):905-12
pubmed: 9657530
Trends Pharmacol Sci. 1995 Mar;16(3):89-97
pubmed: 7540781
PLoS One. 2012;7(2):e31439
pubmed: 22359591
J Neurochem. 2020 Jan;152(2):235-251
pubmed: 31613384
J Neurol Sci. 1995 Oct;132(2):156-61
pubmed: 8543941
Brain. 2009 May;132(Pt 5):1366-75
pubmed: 19153147
Nat Neurosci. 2006 Aug;9(8):1050-6
pubmed: 16829955
Clin Ther. 2008 May;30(5):813-24
pubmed: 18555929
Drugs. 2014 Dec;74(18):2175-90
pubmed: 25385556
Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):8155-9
pubmed: 1518841
Lancet. 2015 Aug 29;386(9996):896-912
pubmed: 25904081
Nat Neurosci. 2002 Feb;5(2):169-74
pubmed: 11802171
Ann Clin Transl Neurol. 2021 Jan;8(1):224-237
pubmed: 33348472
Neurol India. 2018 Mar-Apr;66(Supplement):S15-S25
pubmed: 29503324
Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1719-23
pubmed: 7878047
Eur J Neurosci. 1998 Aug;10(8):2565-73
pubmed: 9767387
Br J Pharmacol. 2013 Nov;170(5):1112-29
pubmed: 23992580
ChemMedChem. 2014 Dec;9(12):2653-60
pubmed: 25338762
Transl Psychiatry. 2016 Mar 08;6:e753
pubmed: 26954980
J Recept Signal Transduct Res. 2004 Aug;24(3):165-205
pubmed: 15521361
Ageing Res Rev. 2020 Jan;57:100994
pubmed: 31765822
CNS Neurol Disord Drug Targets. 2006 Jun;5(3):345-53
pubmed: 16787233
Neuropsychopharmacology. 2009 Mar;34(4):1078-86
pubmed: 18987627
Br J Pharmacol. 2018 Feb;175(4):590-605
pubmed: 29130486
Neurology. 1994 Oct;44(10):1777-80
pubmed: 7936219
Can J Physiol Pharmacol. 2000 Jan;78(1):7-11
pubmed: 10741754
Neurology. 2007 Apr 17;68(16):1262-7
pubmed: 17438216
Neuropsychopharmacology. 2010 Feb;35(3):806-17
pubmed: 19956086
Eur J Pharmacol. 1990 Jan 17;175(3):333-40
pubmed: 1969802
Synapse. 1993 Jun;14(2):169-77
pubmed: 8101394
J Neurosci. 2016 Feb 03;36(5):1577-89
pubmed: 26843639
Neural Regen Res. 2022 Apr;17(4):867-874
pubmed: 34472487
Nucl Med Biol. 2007 Feb;34(2):195-203
pubmed: 17307127
Neuroreport. 2013 Jul 10;24(10):509-14
pubmed: 23636255
PLoS One. 2013 Oct 18;8(10):e76595
pubmed: 24204641
Neuron. 2003 Sep 11;39(6):889-909
pubmed: 12971891
CNS Drugs. 2010 Oct;24(10):829-41
pubmed: 20839895
Biochim Biophys Acta. 2009 Jul;1792(7):688-702
pubmed: 19007882
Synapse. 2009 Sep;63(9):717-28
pubmed: 19425052
Synapse. 2009 Jun;63(6):476-83
pubmed: 19217027
Neuroreport. 1997 Nov 10;8(16):3553-8
pubmed: 9427325
Curr Pharm Des. 2003;9(8):643-71
pubmed: 12570797
J Neurochem. 2006 May;97(4):1089-103
pubmed: 16606355
Arch Neurol. 2012 Oct;69(10):1326-31
pubmed: 22825369
Br J Pharmacol. 2015 Feb;172(4):1124-35
pubmed: 25339241
Biol Psychiatry. 2009 Jun 15;65(12):1024-31
pubmed: 19251247
Parkinsonism Relat Disord. 2012 Jun;18(5):488-93
pubmed: 22326237
Neurochem Int. 2001 Jan;38(1):31-42
pubmed: 10913686